- Freia has added a second line Dermogel Hand Sanitizer with alcohol to meet customer demand.
- Freia has confirmed sales orders of N95 Facemasks into the European market.
- Freia has sourced this catalogue of facemasks available for the UK and North American markets.
- Freia has secured production sourcing for these medical masks to meet increasing demand.
- Freia's pharmaceutical own production facilities and supply chain have the capability to rapidly meet increased capacity of its Dermogel Hand Sanitizer line.
MONTRÉAL, April 09, 2020 (GLOBE NEWSWIRE) -- Elixxer Ltd. (TSX-V: ELXR) (OTC-QB: ELIXF) (FRA: 2LQA) ("ELIXXER" or the "Company"): Elixxer's pharmaceutical partner, Freia, has confirmed to the company that their production facilities are capable to quickly increase production to meet demand of their Dermogel hand sanitizer per month. The company has also begun to add alcohol to the formulation to answer the demand from customers.
Freia has also sourced and begun to sell N95, KN95, FFP2 and EN14683:2014 facemasks. Their first order was 33,000 N95 masks and the company continues to build their order book. The production at Freia's source can supply all Freia orders.
Freia and Elixxer are committed to bring these and other pharmaceutical medical products to markets to protect and enhance the overall health of consumers throughout Europe, the UK and North America.
About Elixxer Ltd.)
ELXR Ltd. is a Canadian public company listed on the TSX Venture Exchange (TSX-V: ELXR), the US OTC-QB exchange (OTCQB: ELIXF) and Frankfurt (FRA: 2LQA)
Through its partners ELXR presently has significant interests in Australia, Jamaica, Switzerland, Italy and Canada.
For further information please contact:
President, John McMullen, +1-416-803-0698, john@elixxer.com
Mr. Marco Santini, Freia Farmaceutici, marco.santini@freiafarmaceutici.it
Caution Regarding Press Releases
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Notice Regarding Forward Looking Statements
This press release may contain forward-looking statements with respect to Elixxer and its operations, strategy, investments, financial performance and condition. These statements can generally be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Elixxer could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, government regulation and the factors described under "Risk Factors and Risk Management" in Elixxer's most recent Management's Discussion and Analysis filed on SEDAR (www.sedar.com). The cautionary statements qualify all forward-looking statements attributable to Elixxer and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release, and Elixxer has no obligation to update such statements, except to the extent required by applicable securities laws.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/84973059-6314-4409-bf42-c9ba9800ab33
